FBR Capital analsyt Vernon Bernardino reiterated an Outperform rating and $16 price target on Conatus Pharmaceuticals (NASDAQ: CNAT) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE